Table 2.
Study and patient characteristics.
| Study | CAMEO-DAPA | EMPIRE-HF | SIMPLE | |||
|---|---|---|---|---|---|---|
| Country | USA | Denmark | Denmark | |||
| Duration | 24 weeks | 12 weeks | 13 weeks | |||
| Intervention | Dapagliflozin 10 mg daily (n = 21) | Placebo (n = 17) | Empagliflozin 10 mg daily (n = 35) | Placebo (n = 35) | Empagliflozin 25 mg daily (n = 18) | Placebo (n = 19) |
| Age (years) | 67 ± 9 | 67 ± 9 | 59 ± 8 | 56 ± 11 | 65 ± 9 | 63 ± 11 |
| Female | 14 (67%) | 11 (65%) | 3 (9%) | 4 (11%) | 7 (39%) | 3 (16%) |
| White | 35 (7.2%) | 34.5 (5.5%) | 35 (100%) | 35 (100%) | NA | NA |
| BMI | 35 ± 7.2 | 34.5 ± 5.7 | 29 ± 5 | 30 ± 6 | 32 ± 6 | 31 ± 6 |
| NYHA II | 7 (33%) | 5 (29%) | 27 (77%) | 31 (89%) | 8 (53%) | 4 (25%) |
| NYHA III | 14 (67%) | 12 (71%) | 8 (23%) | 4 (11%) | 0 | 1 (6%) |
| LVEF (%) | 61 ± 6 | 63 ± 6 | NA | NA | 55 ± 8 | 59 ± 7 |
| ACEi/ARB | 6 (29%) | 4 (24%) | 25 (71%) | 29 (83%) | 17 (94%) | 13(68%) |
| ARNI | — | — | 9 (26%) | 4 (11%) | NA | NA |
| Beta-blocker | 6 (29%) | 9 (53%) | 32 (91%) | 31 (89%) | 9 (50%) | 9 (48%) |
| MRA | 7 (33%) | 6 (35%) | 22 (63%) | 20 (57%) | 1 (6%) | 0 |
| Diuretics | 12 (57%) | 12 (71%) | 24 (69%) | 26 (74%) | 2 (11%) | 4 (21%) |
Abbreviations: ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; ARNI: angiotensin receptor/neprilysin inhibitor; BMI: body mass index; LVEF: left ventricular ejection fraction; MRA: mineralocorticoid receptor blocker; NYHA: New York Heart Association; USA: United States of America.